Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats

Toxicon

Volumn 54, Issue 6, 2009, Pages 857-861

  Sakamoto, Takashi ^a   Torii, Yasushi ^b,c   Takahashi, Motohide ^d   Ishida, Setsuji ^d   Goto, Yoshitaka ^b   Nakano, Hirotoshi ^b   Harakawa, Tetsuhiro ^b   Ginnaga, Akihiro ^b   Kozaki, Shunji ^c   Kaji, Ryuji ^e  

^a National Center Hospital of Neurology and Psychiatry   (Japan)

^b KAKETSUKEN   (Japan)

^c Osaka City University   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Clostridium botulinum; CMAP; Mouse ip LD50

Indexed keywords

BOTULINUM TOXIN A;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL ANIMAL; FEMALE; GASTROCNEMIUS MUSCLE; LD 50; MUSCLE ACTION POTENTIAL; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PAIN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RELIABILITY;

ACTION POTENTIALS; ANIMALS; BOTULINUM TOXIN TYPE A; FEMALE; LETHAL DOSE 50; MICE; MICE, INBRED ICR; MUSCLE, SKELETAL; RATS;

ANIMALIA; CLOSTRIDIUM BOTULINUM; MUS; RATTUS;

EID: 68949131091     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.06.020     Document Type: Article

References (16)

1. Aoki K.R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39 12 (2001) 1815-1820
2. Bigalke H., Wohlfarth K., Irmer A., and Dengler R. Botulinum A toxin: Dysport improvement of biological availability. Exp. Neurol. 168 1 (2001) 162-170
3. Cichon Jr. J.V., McCaffrey T.V., Litchy W.J., and Knops J.L. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 105 2 (1995) 144-148
4. Hallis B., James B.A., and Shone C.C. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J. Clin. Microbiol. 34 8 (1996) 1934-1938
5. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 75 7 (2004) 951-957
6. Kessler K.R., and Benecke R. The EDB test - a clinical test for the detection of antibodies to botulinum toxin type A. Mov. Disord. 12 1 (1997) 95-99
7. Pearce L.B., Borodic G.E., First E.R., and MacCallum R.D. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol. Appl. Pharmacol. 128 1 (1994) 69-77
8. Rosales R.L., Bigalke H., and Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur. J. Neurol. 13 Suppl. 1 (2006) 2-10
9. Sadick N.S. Botulinum toxin type B. Dermatol. Surg. 29 4 (2003) 348-351
10. Sakaguchi G., Ohishi I., and Kozaki S. Purification and oral toxicities of Clostridium botulinum progenitor toxins. In: Lewis G.E. (Ed). Biomedical Aspects of Botulism (1981), Academic Press, New York 21-34
11. Sakaguchi G. Clostridium botulinum toxins. Pharmacol. Ther. 19 2 (1983) 165-194
12. Sesardic D., McLellan K., Ekong T.A., and Das R.G. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacol. Toxicol. 78 5 (1996) 283-288
13. Straughan D. Progress in applying the three Rs to the potency testing of botulinum toxin type A. Altern. Lab Anim. 34 3 (2006) 305-313
14. Takahashi M., Kameyama S., and Sakaguchi G. Assay in mice for low levels of Clostridium botulinum toxin. Int. J. Food Microbiol. 11 3-4 (1990) 271-277
15. Wictome M., Newton K., Jameson K., Hallis B., Dunnigan P., Mackay E., Clarke S., Taylor R., Gaze J., Foster K., and Shone C. Development of an in vitro bioassay for Clostridium botulinum type B neurotoxin in foods that is more sensitive than the mouse bioassay. Appl. Environ. Microbiol. 65 9 (1999) 3787-3792
16. Yoneda S., Shimazawa M., Kato M., Nonoyama A., Torii Y., Nishino H., Sugimoto N., Kozaki S., and Hara H. Comparison of the therapeutic indexes of different molecular forms of botulinum toxin type A. Eur. J. Pharmacol. 508 1-3 (2005) 223-229